Cancer Treatment Reviews
Volume 24, Issue 2 , Pages 113-118 , April 1998

Medical management of advanced gastric cancer

References 

  1. Dupont JB, Lee JR, Burton GR, Cohn I. Adenocarcinoma of the stomach: review of 1497 cases. Cancer. 1978;41:941–953
  2. In:  Whelan SL,  Parkin DM,  Masuyer E editor. Trends in Cancer Incidence and Mortality. 4th edition. Scientific Publication no. 102. Lyon: IARC; 1993;
  3. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer. 1990;62:440–443
  4. Allum WH, Powell DJ, McConkey CC, Fielding JW. Gastric cancer: a 25-year review. Br J Surg. 1989;76:535–540
  5. Glimelius B, Hoffman K, Haglund U. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994;5:189–190
  6. Murad AM, Santigao FF, Petroianu , et al.  Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer. 1993;72:37–41
  7. Pyrhönen S, Kuitunen T, Nyandoto P, Louri M. Randomised comparison of FEMTX plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587–591
  8. Glimelius B, Hoffman K, Graf W, et al.  Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol. 1995;6:267–274
  9. Glimelius B, Ekstrom K, Hoffman K, et al.  Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–168
  10. Moynihan T, Henson R, Anderson T, et al.  Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol. 1988;11:461–464
  11. Comis R. Integration of chemotherapy into combined modality treatment of solid tumours. Cancer Treat Rev. 1974;1:22–23
  12. Kolaric K, Potrebica V, Cevek J. Phase II clinical trial of 4′-epi-doxorubicin in metastatic solid tumours. J Cancer Res Clin Oncol. 1983;106:148–152
  13. Scarffe JH, Kenny JB, Johnson RJ, et al.  Phase II trial of epirubicin in gastric cancer. Cancer Treat Rep. 1985;69:1275–1277
  14. Cazap E, Bruno M, Levy D, et al.  Phase II trial of 4′-epi-doxorubicin in advanced gastric cancer. In: 4th edition. Proc Am Soc Clin Oncol. 5:1986;p. 91; (abstract 356)
  15. Moertel CG, Levin PT. Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rev. 1979;63:1863–1872
  16. Sulkes A, Smythe J, Sessa C, et al.  Docetaxel (Taxotere™) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer. 1994;72:380–383
  17. Futatsuki K, Wakui A, Nakao I, et al.  Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother. 1994;21:1033–1038
  18. Leichman L, Berry BT. Cisplatin therapy for adenocarcinoma of the stomach. Semin Oncol. 1991;18(Suppl. 3):25–33
  19. Kovach JS, Moertel CG, Schutt AJ, et al.  A controlled study of combined 1,3-bis-(2 chloroethyl)-1-nitrosourea and 5-FU therapy for advanced gastric and pancreatic cancer. Cancer. 1974;33:563–567
  20. Ajani JA, Fairweather J, Dumas P, et al.  A phase II study of Taxol® in patients with advanced untreated gastric carcinoma. In: 4th edition. Proc Am Soc Clin Oncol. 16:1997;p. 263a; (abstract 933)
  21. Bruckner H, Lokich J, Stablein D. Studies of Baker's antifol, methotrexate and razoxane in advanced gastric cancer: a Gastrointestinal Tumour Study Group report. Cancer Treat Rep. 1982;66:1713–1717
  22. Moertel CG, Mittelman JA, Bakemeier RF, et al.  Sequential and combination chemotherapy of advanced gastric cancer. Cancer. 1976;38:676–682
  23. O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al.  Drug therapy: etoposide (VP-16-213). In: Current status of an active anticancer drug. 4th edition. N Engl J Med. 213:1985;p. 692–701
  24. Enzig A, Kelson DP, Change E. Phase II trial of carboplatin in patients with adenocarcinomas of the upper gastrointestinal tract. Cancer Treat Rep. 1985;69:1453–1454
  25. Christman K, Kelsen D, Saltz L, Tarassoff PG. Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer. 1994;73:5–7
  26. Baker LH, Talley RW, Matter R, et al.  A Southwest Oncology Group study. In: Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. 4th edition. Cancer. 38:1976;p. 1–7
  27. Levi JA, Fox RM, Tattersall MH, et al.  Analysis of a prospectively randomised comparison of doxorubicin versus 5-FU, doxorubicin and BCNU in advanced gastric cancer: implications for future studies. L Clin Oncol. 1986;4:1348–1355
  28. Schnitzler G, Quesser W, Heim ME, et al.  Phase III study of 5-FU and carmustine vs. 5-FU, carmustine and doxorubicin in advanced gastric cancer. Cancer Treat Rep. 1986;70:477–479
  29. McDonald J, Schein PS, Woolley PV, et al.  5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 1980;93:533–536
  30. Douglass HO, Lavin PT, Goudsmit A, et al.  An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin and 5-FU in advanced measurable gastric cancer (EST 2277). J Clin Oncol. 1984;2:1372–1381
  31. Cullinan SA, Moertel CG, Fleming TR, et al.  A comparison of three chemotherapy therapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin and mitomycin. J Am Med Assoc. 1985;253:2061–2067
  32. The Gastrointestinal Tumour Study Group. Triazinate and platinum efficacy in combination with 5-FU and doxorubicin: results of a 3-arm randomised trial in metastatic gastric cancer. J Natl Cancer Inst. 1988;80:1011–1015
  33. Klein H, Wickramayake PD, Dieterle F, et al.  High dose MTX/5-FU and adriamycin for gastric cancer. Semin Oncol. 1983;10:29–31
  34. Wils O, Klein H, Wagner D, et al.  Sequential high dose methotrexate and fluorouracil combined with doxorubicin: a step forward in the treatment of gastric cancer. J Clin Oncol. 1991;9:827–831
  35. Preusser P, Wilke H, Achterrath W, et al.  Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol. 1989;7:1310–1317
  36. Wilke H, Preusser P, Fink U, et al.  Preoperative chemotherapy in locally advanced and non-resectable gastric cancer: a phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol. 1989;7:1318–1326
  37. Kelson D, Atiq OT, Saltz L, et al.  FAMTX versus etoposide, doxorubicin and cisplatin: a randomised trial in gastric cancer. J Clin Oncol. 1992;10:541–548
  38. Kim NK, Park YS, Heo DS, et al.  A phase III randomised study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin-C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 1993;71:3813–3818
  39. Coccini G, Bella M, Zironi S, et al.  Fluorouracil, doxorubicin and mitomycin-C versus FELV chemotherapy in advanced gastric cancer: A prospective randomised trial. In: Italian Oncology Group for Clinical Research. 4th edition. J Clin Oncol. 12:1994;p. 2687–2693
  40. Webb A, Cunningham D, Scarffe JH, et al.  A randomised trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced oesophago-gastric cancer. J Clin Oncol. 1997;15:261–267
  41. Cullinan S, Moertel C, Wieand H, et al.  Controlled evaluation of three drug combinations versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol. 1994;12:412–416
  42. Findlay M, Cunningham D, Norman A, et al.  A phase II study in advanced gastric cancer using epirubicin and cisplatin in combination with continuous 5-FU (ECF). Ann Oncol. 1994;5:609–616
  43. Zaniboni A, Barni S, Labianca R, et al.  Epirubicin, cisplatin and continuous infusion of 5-fluorouracil as an active and safe regimen for patients with advanced gastric cancer: an Italian Group Study of Digestive Tract Cancer (GISCAD) report. Cancer. 1995;76:1694–1699
  44. Bamias A, Hill ME, Cunningham D, et al.  Epirubicin, cisplatin and protracted venous infusion of 5-fluorouracil for oesophago-gastric adenocarcinoma: response, toxicity, quality of life and survival. Cancer. 1996;76:1978–1985
  45. Fraile RJ, Baker LH, Buroker TR, et al.  Pharmacokinetics of 5-FU administered orally, by rapid intravenous infusion and by slow infusion. Cancer Res. 1980;40:2223–2228
  46. Eitenne MC, Bernard S, Fischel JL, et al.  Dose reduction without loss of efficacy of 5-FU and cisplatin combined with folinic acid: in vitro studies on human head and neck carcinoma cell lines. Br J Cancer. 1991;63:372–377
  47. Cascinu S, Labianca R, Alessandroni P, et al.  Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol. 1997;15:3313–3319
  48. Cohen JL, Irwin LE, Marshall GJ, et al.  Clinical pharmacology of oral and intravenous 5-FU. Cancer Chemother Rep. 1974;58:723–731
  49. Heggie GD, Sommadossi J-P, Cross DS, et al.  Clinical pharmacokinetics of 5-FU and its metabolites in plasma, urine and bile. Cancer Res. 1987;47:2203–2206
  50. Baker SD, Khor SP, Adjei AA, et al.  Pharmacokinetic, oral bioavailability and safety study of 5-FU in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol. 1996;14:3085–3096
  51. Shirao K, Yasuhiro S, Hitoshi K, et al.  Phase I/II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol. 1997;15:921–927
  52. Sukuki T, Ochiai T, Nagata N, et al.  High dose chemotherapy with autologous bone marrow transplantation for the treatment of advanced gastric cancer. Cancer. 1993;72:2537–2542

PII: S0305-7372(98)90077-9

Cancer Treatment Reviews
Volume 24, Issue 2 , Pages 113-118 , April 1998

Article Tools